Literature summary for 2.7.7.49 extracted from

Jamburuthugoda, V.K.; Chugh, P.; Kim, B.
Modification of human immunodeficiency virus type 1 reverse transcriptase to target cells with elevated cellular dNTP concentrations (2006), J. Biol. Chem., 281, 13388-13395.

Search for more literature for 2.7.7.49

Application

Application	Comment	Organism
medicine	the modified vector system harboring the viral DNA polymerase mutant with reduced dNTP binding affinity can be a potential gene delivery system for the specific transduction of cells with high dNTP concentrations, such as tumor cells.The identification and use of unique cellular and virological factors essential for the specificity of viral based vectors can contribute to the development of safe and effective gene delivery tools	Human immunodeficiency virus 1

Protein Variants

Protein Variants	Comment	Organism
Q151N	mutant is catalytically active only at high dNTP concentrations because of its reduced dNTP binding affinity. The modified HIV-1 vector harboring the Q151N mutant reverse transcriptase preferentially transduces tumor cells containing higher cellular dNTP concentrations than primary cells (e.g. human lung fibroblasts and human keratinocytes). The wild type HIV-1 vector transduces both human lung fibroblasts and tumor cells. The Q151N vector fails to transduce human lung fibroblasts and keratinocytes but efficiently transduces tumor cells. Pretreatment of human lung fibroblasts with deoxynucleosides, which increase cellular dNTP pools, enables the mutant vector to transduce human lung fibroblasts, suggesting that the transduction failure of the RT mutant vector to primary cells is because of inefficient reverse transcription in low cellular dNTP environments	Human immunodeficiency virus 1

Organism

Organism	UniProt	Comment	Textmining
Human immunodeficiency virus 1	-	-	-

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)